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Abstract
Purpose of review
To improve our clinical understanding of facial onset sensory and
motor neuronopathy (FOSMN).
Recent findings
We identified 29 new cases and 71 literature cases, resulting in
a cohort of 100 patients with FOSMN. During follow-up, cognitive
and behavioral changes became apparent in 8 patients, suggesting
that changes within the spectrum of frontotemporal dementia
(FTD) are a part of the natural history of FOSMN. Another new
finding was chorea, seen in 6 cases. Despite reports of autoanti-
bodies, there is no consistent evidence to suggest an autoimmune
pathogenesis. Four of 6 autopsies had TAR DNA-binding protein
(TDP) 43 pathology. Seven cases had genetic mutations associated
with neurodegenerative diseases.
Summary
FOSMN is a rare disease with a highly characteristic onset and pattern of disease progression
involving initial sensory disturbances, followed by bulbar weakness with a cranial to caudal
spread of pathology. Although not conclusive, the balance of evidence suggests that FOSMN
is most likely to be a TDP-43 proteinopathy within the amyotrophic lateral sclerosis–FTD
spectrum.
Facial onset sensory and motor neuronopathy (FOSMN) is a rare neurologic syndrome first
described by Vucic et al. in 2006.1 It has a characteristic phenotype with paresthesia and
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numbness arising within the trigeminal nerve distribution,
which slowly spreads to the scalp and thereafter descends to
the neck, upper trunk, upper extremities, and in some cases
to the lower extremities. The initial sensory disturbance may
begin in a perioral location, or affect one or more of the
trigeminal branches unilaterally and then become bilateral,
or be bilateral from the beginning. Lower motor neuron
features present later or concurrently with the sensory defi-
cits. These include dysphagia, dysarthria, fasciculations,
muscle weakness, and muscle atrophy, along the same
rostral-caudal direction.2 In general, only the lower motor
neuron system is involved, although upper motor neuron
signs have been reported in a few cases.3–11
Pathogenesis is uncertain. Initial indications suggested an auto-
immune basis since autoantibodies have been reported as well as
a partial and subjective response to immunotherapy.1,3,4,6,8,12–16
The finding of TAR DNA-binding protein (TDP) 43 pa-
thology at autopsy in several FOSMNcases, however, implies
a neurodegenerative mechanism and a likely association with
amyotrophic lateral sclerosis (ALS).8–10,17
The objective of this study is to expand our understanding of
FOSMN by evaluating clinical findings and the natural his-
tory of the disease in a larger sample than hitherto available
and to review the current literature.
Methods
Updated case series
FOSMN is an extremely rare disorder, with only 38 cases
reviewed to date.2 We provide an updated case series by
describing new incident cases and cases identified through
literature search.
Incident cases were seen at the following specialized (neuro-
muscular) clinics: University Medical Centre Utrecht (The
Netherlands), Brighton, and Sussex University Hospitals
NHS Trust (UK), Rostock University Hospital (Germany),
University Hospital i Polite`cnic La Fe Valencia (Spain), Uni-
versity Hospital Cl´ınico de Santiago (Spain), University Hos-
pital de Bellvitge in Barcelona (Spain), University Hospital
Haukeland Bergen (Norway), Foundation of the Carlo Besta
Neurological Institute IRCCS Milan (Italy), National Human
Genome Research Institute, Bethesda (United States of
America), and the Federal University of São Paulo (Brazil).
Several patients self-reported to us, some through the
FOSMN patient organization, in which case the treating
physician was contacted to obtain medical records. At pres-
ent, there are no formal diagnostic criteria for FOSMN. The
diagnosis was therefore made based on excluding other po-
tential causes and expert opinion.
We performed a systematic search of the literature with the
objective of identifying FOSMN cases that were not included
in previous reviews. Titles and abstracts were screened, and
relevant full-text articles were retrieved. Corresponding
authors were also contacted for additional details (figure 1).
Published cases, not included in reviews before, and our
incident cases will be reported separately as novel cases.
Clinical data
We extracted the following data from published cases and the
medical records of the incident cases: sex, age at onset, dis-
ease duration, bulbar signs, sensory deficits, weakness of ex-
tremities, uppermotor neuron signs, laterality, cerebral spinal
fluid results, antibody testing, results of imaging, genetic
analysis, neurophysiologic evaluation, type of therapy and
response, biopsy, need for a gastric feeding tube or percuta-
neous endoscopic gastrostomy, need for noninvasive venti-
lation, cause of death, and autopsy findings.
Follow-up data on previously published cases and available
longitudinal data from the incident cases were included.13,16,18
We encoded and stored the data in a secure, password-
protected database.
Pathophysiology
There are 2 leading hypotheses with regard to the cause of
FOSMN, namely, that it is either a neurodegenerative or an
autoimmune disorder. From our cases and the literature, we
extracted data on ancillary investigations, response to treat-
ment, disease course, and postmortem findings. These data
were subsequently categorized as supportive of a neurode-
generative or autoimmune etiology.
Results
Updated case series and clinical findings
We identified a total of 29 incident cases. Our literature search
yielded 26 full-text articles reporting on a total of 64 patients
with FOSMN, of which 29 were not described in a review
before.1,3–16,18–24 We further identified 7 abstracts/posters/
supplements reporting on 11 potential cases and 2 articles
mentioning 10 FOSMN cases without further patient
characteristics.25,26 After reaching out to the corresponding
authors, we received a detailed poster on 7 patients with
FOSMN.17 We chose not to include the other 14 possible
There are 2 leading hypotheses with
regard to the cause of FOSMN,
namely, that it is either
a neurodegenerative or an
autoimmune disorder.
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patients with FOSMN due to the limited information in the
abstracts. This led to a total of 100 patients with FOSMN. The
main clinical findings of the 28 cases that had not been reported
previously are summarized in table e-1, links.lww.com/CPJ/
A171. The baseline characteristics for all 100 FOSMN cases are
described in table 1. Most cases developed progressive sensory
deficits, starting in the trigeminal nerve distribution and slowly
spreading to the scalp, neck, shoulders, upper extremities, and
in a few cases to the lower extremities. Later (in some cases
concurrently), lower motor signs developed, starting in the face
and spreading through the same pattern as the sensory dis-
turbances, resulting in bulbar symptoms (dysarthria and dys-
phagia), fasciculations, atrophy, and weakness of the involved
muscles (figure 2). Asymmetrical presentation of the symp-
toms (initially) occurred in 48 of the cases, in whom the first
affected side remained more severely affected as the disease
progressed despite involvement of the contralateral side. Lower
motor neuron signs were observed in all FOSMN cases. Upper
motor neuron signs, such as brisk reflexes, Babinski sign, and
clonus, were reported in 27 cases.3–11,14
Natural history
The mean age at onset is approximately 55 years (range 7–78
years). The rate of progression is highly variable, and survival
ranges from 14 months to over 46 years.1,3–23 Ninety-one
percent of the cases started with progressive facial sensory
impairment, followed by motor involvement. In a single case,
sensory symptoms slowly developed 10 years after onset of
the motor deficits.13 Two patients developed high-frequency
sensorineural hearing loss developed, which started mid-50s
(cases 1 and 2).13 Case 4 from our case series (table e-1,
links.lww.com/CPJ/A171) also complained of hearing loss;
however, results of ancillary investigations were not avail-
able. Sleeping problems were described in 2 cases; case 9 had
signs suggesting REM sleep behavioral disorder, and in case
1,13 this was confirmed by polysomnography. (Pseudo)
Figure 1 Summary of the results from the literature search
The search was performed on September 1, 2019, using PubMed and EMBASE on articles from January 1, 2006, to September 1, 2019, reporting on FOSMN.
Titles and abstracts were screened, and relevant full-text articles were retrieved. References were screened for additional studies. FOSMN = facial onset
sensory and motor neuronopathy.
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choreoathetosis, was seen in 6 patients (cases 21, 22, 25, 26,
27, and a literature patient who was followed up on).16
Ninety-seven percent of the patients developed bulbar
symptoms.1,3–11,13,14,16–23 Weight loss resulting from dys-
phagia in FOSMN may be severe, and in 34 cases, gastro-
stomy was indicated.1,3,4,7,8,10,11,13,14,16–19,23 The mean
disease duration before placement was 5 (1–14) years after
onset of the symptoms. Fourteen patients required non-
invasive ventilation.8,11,16,19
Of the 39 patients who died, the mean disease duration was
7.5 years. Of the known causes of death, 23 patients died as
a result of progressive bulbar weakness, leading to aspiration
pneumonia or respiratory failure.3,5,7,8,10,12,17,20,21,23
Behavioral changes and cognitive impairment
Five patients developed progressive behavioral changes and
were clinically diagnosed with comorbid behavioral variant
frontotemporal dementia (bvFTD) by the treating neurologist.
Review of the medical records indeed shows that the Rascovsky
criteria are met.27 One patient also showed progressive be-
havioral changes strongly suggestive of bvFTD, but no formal
diagnosis was made. Considering FOSMN is a potential mimic
(or perhaps even an atypical formal form) of ALS, patients are
commonly referred to motor neuron disease (MND) clinics.
Given that ALS and FTD are highly related disorders, screening
for cognitive and behavioral changes has become part of the
standard workup in MND, most frequently using the Edin-
burgh Cognitive and Behavioral ALS screen (ECAS). There-
fore, ECAS data for 6 FOSMN cases, seen at MND clinics,
were available to us (one of the patients diagnosed with bvFTD
also underwent an ECAS). In total, neuropsychological data
were available for 11 patients, of which 8 demonstrated changes
within the FTD spectrum (72%). Three patients showed
normal ECAS results and no behavioral changes.
There are no available data on cognition and behavioral
changes in the remaining 89 cases; therefore, we are unable to
provide an estimate of the frequency of these changes in
FOSMN. A brief summary of neuropsychological findings of
these cases is provided in table 2.
The first case is a man (patient 1),13 who at age 59 years (17
years after onset) began to complain of deteriorating mem-
ory for recent events, had difficulty planning activities, and
became apathetic with blunted empathy or emotional
responses, thereby meeting the criteria for possible bvFTD.
Cognitive screening using the ECAS did not demonstrate
memory deficits, but did show that he scored under the
cutoff for verbal fluency.
The second case is a 45-year-old man (patient 7),13 who 12
years after onset of FOSMN became very irritable with social
withdrawal and became obsessive and mildly apathetic. Mem-
ory for recent events and concentration abilities were also di-
minished. He also meets the criteria for possible bvFTD.
Table 1 Demographics and characteristics of patients
with FOSMN
n n tested ina
Patients 100
Male 67
Mean age at onset, y (range) 55 (7–78)
Mean disease duration, y/m 8.2 y
Range 14 m–46 y
Patients who are still alive 61 (8.6 y)
Patients who died 39 (7.5 y)
Male 29 (7.3 y)
Female 9 (6.8 y)
Unknown 1 (6 y)
Onset with facial sensory symptoms 91 100
Sensory deficits
Face 96 100
Upper extremities 40 100
Lower extremities 11 100
Motor impairment
Bulbar symptoms 97 100
Upper extremities 77 100
Lower extremities 23 100
Upper motor neuron signs 27 95
Antibodies positive 14
Neurophysiologic tests
Blink reflex abnormal 94 96
EMG: D/R signs 94 94
NCS: SNAP amplitude reduced 53 86
Treatment
Immunotherapy started 48 95
Any form of response 10
GFT/PEG placed or indicated 34
Patients deceased 39
Cause of death
Aspiration pneumonia/respiratory failure 23
Refusal of enteral nutrition 1
Lung cancer/trauma 2
Unknown 13
Abbreviations: D/R = degeneration/regeneration signs; EMG = electromy-
ography; FOSMN = facial onset sensory and motor neuronopathy; GFT =
gastric feeding tube; NCS = nerve conduction study; PEG = percutaneous
endoscopic gastronomy; SNAP = sensory nerve action potential.
a n tested in = number of patients in which having the feature is described/
tested.
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Another case with signs of bvFTD is patient 8. At age 69
years, after 22 years of disease, he developed short-term
memory loss, aphasia, and difficulty following instructions.
Episodes of confused nocturnal wandering occurred soon
after sleep onset, during which he held the delusion that his
wife was an imposter and could become aggressive when
challenged. Unfortunately, limited information was available
from medical records, but aphasia and behavioral changes
were the most prominent features in this case. It is unclear
whether we should classify this patient as having primary
progressive aphasia or as cognitive and behavioral impair-
ment according to the current Strong criteria for fronto-
temporal spectrum disorder in MND.28 The latter is a term,
which is applicable to patients with cognitive and behavioral
changes within the spectrum of FTD, but that do not meet
the formal criteria. Unfortunately, the patient died before full
neuropsychological evaluation could be achieved. Brain
MRIs were normal in all 3 cases.
Two patients showed cognitive impairment according to the
ECAS without behavioral changes. Patient 2 and patient 6,
a Spanishpatient,with brain atrophy, predominating in the right
frontotemporal lobes. His ECAS showed mild cognitive im-
pairment (executive functioning), and another memory
screening test (M@T) showed mild impairment in long-term
episodic memory. Because the ALS-FTD-Q is not validated in
Spanish, a semistructured ECAS interview and the FRSBE
questionnaire were performed with normal results.24,29
Differential diagnosis
At present, there is no diagnostic test that can definitively
confirm FOSMN nor are there existing diagnostic criteria. The
diagnosis is based on expert opinion and relies predominantly
on a history of facial onset sensory symptoms, followed by facial
weakness and a subsequent cranial-caudal spread of symptoms.
Other causes need to be ruled out, making FOSMN a diagnosis
by exclusion. There is considerable heterogeneitywith regard to
the presentation. For instance, some patients did not seek
medical attention for the facial sensory signs. The interval be-
tween the onset of facial sensory signs and weakness can range
from years to simultaneous onset. There was 1 case where
subtle sensory symptoms only developed 10 years after onset of
the motor deficits.13 The rate of progression differs consider-
ably, with some patients developing severe bulbar weakness
within a year compared with patients with exclusively sensory
symptoms for a decade. Therefore, disease duration, rate of
progression, and chief complaint (sensory, motor, or both)
influence the differential diagnosis and the workup.
In patients with isolated sensory signs, idiopathic trigeminal
neuropathy or a central lesion is themain alternative. In cases in
which bulbar weakness is progressive or the predominant fea-
ture, ALS (and ALS mimics) needs to be considered, particu-
larly because it has been suggested that FOSMN is an atypical
form of ALS.30 In most cases, the differential diagnosis is quite
extensive. Table 3 provides an overview of the differential di-
agnosis and most relevant additional investigations.
Laboratory investigations are generally unremarkable. Mildly
elevated CK levels may be found, but never exceeding >5 ×
upper limit normal. CSF is also normal. MRI studies in
patients with FOSMN do not explain the symptoms, al-
though mild to moderate midcervical cord atrophy has been
reported in several cases, bright tongue sign in 3 patients,11
and frontotemporal atrophy in 2 patients.24
Extensive genetic testing has been performed in various cases,
which included ALS genes (C9orf72, FUS, SOD1, TARDBP),
oculopharyngeal muscular dystrophy (PABPN1), Kennedy
disease (AR), panels for spinocerebellar ataxia as well as
Figure 2 Summary distribution abnormalities in FOSMN
Distribution of sensory, motor, and electrophysiologic findings in patients with FOSMN. In all 3 pictures, the darker color represents the higher amount of
patients with abnormalities, showing the cranial-caudal spreading. EMG = electromyography; FOSMN = facial onset sensory and motor neuronopathy;
SNAP = sensory nerve action potential.
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whole-exome sequencing. With a few exceptions (discussed
below), genetic testing has not given any insight so far.
There are several electrophysiologic findings that support
a diagnosis of FOSMN. Blink reflexes are abnormal in all
cases but 2 cases,17 varying from unilateral to bilateral
delayed or absent R1 and/or R2 responses. Needle elec-
tromyography showed signs of denervation and/or rein-
nervation in all patients, spreading in a cranial-caudal
distribution. Sensory nerve conduction studies show re-
duced sensory nerve action potential amplitudes of the up-
per limbs in 62% and in the lower limbs in 4 cases (figure 2).
Pathophysiology
The main hypotheses are that FOSMN is either a neurodegener-
ative or an autoimmune disorder. We reviewed the literature and
extracted data on ancillary investigations, response to immune-
modulating treatment, genetics, disease course, and postmortem
findings and subsequently categorized these data as supportive of
a neurodegenerative or autoimmune etiology (table 4). Auto-
antibodies were present in 14 patients. Three of these cases, 1 with
low-positive ANA and anti-Ro, 1 with anti-sulfo-glucuronyl par-
aglo-boside IgG, anti-myelin-associated glycoprotein IgG, and the
final patient with a monoclonal gammopathy, responded to
immunotherapy.6,8,14 One patient had apparent stabilization of
symptoms,6 1 had partial response of weakness and sensory im-
pairment but thereafter had worsening respiratory symptoms,8
and in the last patient, intravenous immunoglobulin relieved her
facial numbness and improved the blink reflex, but motor symp-
toms worsened. Six other patients also had a form of response to
immunotherapy, but did not report positive immunologic studies.
In a total of 6 patients with FOSMN, an autopsy was
performed.1,5,8,9,17,23 The pathologic studies show loss of
Table 2 Neuropsychological profiles of patients with FOSMN
Patients 1 2 3 4 5 6 7 8 9 10 11
Disease duration at the time of ECAS (y) 17 14 3 4 20 4 NA NA NA NA NA
ECAS cognitive domains NP NP NP NP NP
Language
Verbal fluency X
Executive functioning X X
Memory
Visuospatial X
ECAS behavioral interview X NP NP NP NP NP NP
Behavioral changes NA NA NA NA NA
3/6 Rascovsky criteria p bvFTD X X X X X
Disinhibition x x x
Apathy/inertia x x x
Loss of sympathy/empathy x x x x x
Preservative/compulsive x x x x
Hyperorality
Dysexecutive profile x x
Suggestive of bvFTD but no
neuropsychological evaluation
X
(Pseudo)choreoathetosis X X X
Abbreviations: ECAS = Edinburgh Cognitive and Behavioral ALS Screen; FOSMN = facial onset sensory and motor neuronopathy; FTD = frontotemporal
dementia; NA = not applicable; NP = not performed; p bvFTD = possible behavioral variant FTD according to the Rascovsky criteria.
This table shows the ECAS results (patients 1–6) and behavioral changes of patients with FOSMN. X represents a score under cutoff for the ECAS domain,
indicating cognitive impairment and represents the presence of behavioral changes.
Patients 1, 2, and 6 show cognitive impairment according to the ECAS. Patients 7–11 did not have an ECAS but did have behavioral changes. Patients 1, 7, 9, 10,
and 11 met the criteria for possible bvFTD. Patient 8 showed cognitive and behavioral changes suggestive of bvFTD, but never had a neurophyschological
evaluation. Patients 3 and 4 did not show abnormalities in the ECAS or behavioral changes.
Patient 1 (case 1 Broad and Leigh),13 case 2 (case 2 incident cases), case 3 (case 3 incident cases), patient 4 (case 6 incident cases), patient 5 (case 20 incident
cases), patient 6 (Va´zquez-Costa et al.),24 patient 7 (case 2 Broad and Leigh),13 patient 8 (case 8 case series), patient 9 (Dalla Bella et al.),16 patient 10 (case 21
incident cases), and patient 11 (case 22 incident cases).
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motor neurons in the facial nerve nucleus and hypoglossal
nucleus and cervical anterior horns and loss of sensory neurons
in the main trigeminal sensory nucleus, nucleus of the solitary
tract, and dorsal root ganglia. Four cases had TDP-43–positive
glial inclusions.8,9,17,23 The other 2 cases had no intraneural
inclusions and stained negative for ubiquitin.1,5 Cutaneous
nerve and muscle biopsies show a loss of myelinated fibers and
Wallerian degeneration of the nerves without signs of vasculitis
or amyloid deposition.1,4,5,17,20,21 Genetic analysis was positive
in 7 cases. In 1 case, a heterozygous D90A SOD1 mutation
(familial ALS) was found. There were also 2 cases of a het-
erozygous TARDBP mutation,10,11 of which 1 patient had
a positive family history (2 maternal cousins with definitive
genetic diagnosis of ALS andmotherwith FTD).11 There was 1
case of a heterozygous mutation in TARDBP and in
SQSTM1.24 Furthermutations foundwere a heterozygousVCP
mutation in a patient with a mother with FTD, brother with
spinal-onset ALS, and nephew with IBM11; a patient with
a heterozygous CHCHD10 mutation, whose mother had bi-
lateral eyelid ptosis and Parkinson disease and brother had
chronic exercise intolerance and proximal myopathy11; and 1
case with a genetic mutation in the PABPN1 gene (oculo-
pharyngeal muscular dystrophy).5 Furthermore, 2 patients
with FOSMN were described who underwent whole-exome
sequencing without definitive results, but had a positive fam-
ily history of neurodegenerative diseases, a mother with
Table 3 Differential diagnosis of FOSMN
Disease Tests
Kennedy disease Genetic analysis: CAG repeat androgen receptor chromosome Xq11-12
Sjo¨gren disease Anti-Ro/anti-SS-A, anti-La/anti-SS-B
Schirmer test and Saxon test
Lip biopsy
Tangier disease HDL, triglycerides, and cholesterol spectrum
Nerve biopsy
Genetic analysis: ABCA1 gene
Amyloidosis Genetic analysis: mutation Gelsolin gene
Syringomylia/syringobulbia MRI of the brain and cervical spine
Amyotrophic lateral sclerosis Electrodiagnostic studies: EMG and NCS
Genetic analysis: SOD1, FUS, TARBDP, and C9orf72 genes
Autoimmune-mediated neuropathy Anti-sulfatide antibodies, anti-diasialosyl antibodies, anti-ganglioside antibodies (GD1a and
GT1a), anti-GD1b, ANA, ENA, anti-SGPG IgG, anti-MAG IgG, M-protein screening, rheumatoid
factor, anti–double-stranded DNA, anti-Sm, anti-RNP, anti-Scl79, anti-phospholipids, and anti-
neutrophil cytoplasmic antibodies
Basal meningitis MRI of the brain and CSF
Ischemia MRI of the brain
Myasthenia gravis Antibodies against AChR, MuSK, or LRP-4
Repetitive nerve stimulation
Sarcoidosis ACE, SOL IL-2 receptor
Idiopathic trigeminal neuropathy MRI of the brain
Hereditary motor sensory neuropathy EMG
Genetic analysis: CMT subtypes
Infections Serology serum and/or CSF: HIV, Borrelia, herpes simplex virus 1–2, varicella zoster virus,
leprosy, hepatitis B/C, and Treponema pallidum
Thyroid dysfunction TSH and free T4
Ocular pharyngeal muscular dystrophy Genetic analysis: PABPN1 gene
Brown-Vialetto-Van-Laere syndrome Genetic analysis: SLC52A2 and SLC52A3 genes
Fazio-Londe syndrome Genetic analysis: SLC52A3 gene
Abbreviations: CMT =CharcotMarie Tooth; EMG= electromyography; FOSMN= facial onset sensory andmotor neuronopathy; NCS = nerve conduction study.
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FTD-ALS, and a maternal aunt and grandmother with Par-
kinson disease, and a patient with 2 brothers and a mother with
ALS.11 A positive family history was also seen in incident case
13 (brother died of ALS) and incident case 16 (FTD). To date,
no cases with a positive family history of FOSMN are reported.
Discussion
FOSMN is a rare neurologic syndrome, with a total of 100
documented patients worldwide to date. It typically com-
mences with a trigeminal distribution sensory disturbance,
Table 4 Characteristics of patients with FOSMN, categorized by possible underlying mechanism
Neurodegenerative mechanism Autoimmune mechanism
No positive immunologic studies are
mentioned in 72 cases of CSF analysis, and
immunologic studies in serum are negative
in 78/90 (87%). Positive immunologic studies (13%)
Immunologic studies n cases positive n cases tested
Antinuclear antibody 5 55
Anti-sulfatide IgG 3 17
Anti-MAG IgG 2 19
Monoclonal gammopathy 3 6
Anti-GD1b antibodies 1 33
Anti-Ro 1 43
Anti-dsDNA 1 (slightly) 27
No response to immunotherapy in most
cases.
(Partial) response to immunotherapy
IVIg treatment in 44 cases (20% response)
Stabilization in 1 case6
Partial recovery in 4 cases3,8,14
Response to the first treatment, but not to the second course of treatment in 1 case12
Temporary improvement of blink reflex in 2 cases18
Steroids treatment in 15 cases
Partial response in 1 case8
Plasma exchange treatment in 6 cases
Improvement and no further progression in 1 case12
MRI shows a bright tongue sign in 3
patients11 and frontotemporal atrophy in
2 patients.24
MRI of the brain and cervical spine shows
no signs of inflammation.
2 cases with a positive family history of
ALS/FTD-ALS11
Positive genetic testing: heterozygous
SOD1mutation (n = 1),16 heterozygous
TARDBPmutation (n = 2),10,11 heterozygous
TARDBP and SQSTM1mutations (n = 1),24
heterozygous VCPmutation (n = 1),11 and
heterozygous CHCHD10mutation (n = 1).11
4/6 autopsies had TDP-43 intraneural
inclusions.8,9,17,23
6/6 autopsy cases reported sensory and
motor neuronal degeneration.1,5,8,9,17,23
Abbreviations: ALS = amyotrophic lateral sclerosis; FTD = frontotemporal dementia; FOSMN = facial onset sensory and motor neuronopathy;
IVIg = intravenous immunoglobulin; TDP = TAR DNA-binding protein.
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which progressively engulfs the head, neck, trunk, and upper
and lower extremities. It is followed by motor weakness
spreading along the same craniocaudal distribution, pro-
gressing to bulbar symptoms, weakness of the extremities,
and respiratory motor impairment (figure 2). Over the
course of the disease, patients with FOSMN develop dys-
phagia leading to severe weight loss (requiring gastronomy)
as well as sometimes fatal aspiration pneumonia. Causes of
death in FOSMN are similar to ALS, adding to the view that
there is overlap between the 2 conditions.
Hitherto, little attention has been paid to the presence of
behavioral and cognitive changes in patients with FOSMN.
Six cases are described to have behavioral changes, suggestive
of bvFTD. In 2 patients without behavioral changes, evidence
for executive dysfunction was seen on the ECAS. It seems
that behavioral changes and cognitive changes within the
FTD spectrum may occur in patients with long disease du-
ration, expanding the phenotype of FOSMN. Additional
neuropsychological research in FOSMN seems warranted to
better understand these cognitive and behavioral changes.
Because the cause of FOSMN is unknown, there is no test
that definitively confirms this diagnosis. Patients are there-
fore diagnosed based on expert opinion and by excluding
other disorders that could cause comparable symptoms.
Because there are no formal diagnostic criteria, we cannot be
sure that all documented patients indeed have FOSMN.
Three patients have no sensory symptoms, and 1 patient only
has sensory symptoms in the lower extremities. They do
however all have abnormal blink reflexes indicating tri-
geminal involvement. Until consensus is reached on formal
diagnostic criteria that have been validated, the diagnosis is
based on expert opinion, potentially causing bias in the
present findings.
Thus far, the pathogenesis of FOSMN has remained elusive.
There are 2 main hypotheses. It has been suggested that the
underlying mechanism may be either autoimmune mediated
or neurodegenerative.
An autoimmune origin is supported by the fact that autoanti-
bodieswerepresent in14patientswithFOSMN. Itmust benoted
that the panel of antibodies that was tested varied considerably
between cases and that therefore the percentage of positive cases
could be an underestimation or that yet unidentified antibodies
are involved. However, there seems to be little consistency in the
detected antibodies, and several of these antibodies are associated
with multiple conditions and may be even be found in healthy
individuals. Therefore, these antibodies findings seem to be
nonspecific. A potential underlying autoimmune cause could
possibly be detected with better antibody screening or by using
induced pluripotent stem cell–derived trigeminal neurons.31
Immune-modulating therapy is often initiated in FOSMN, and
(partial) response has been reported, which would also support
an autoimmune etiology. The definition of treatment response
was rather arbitrary, ranging from partial recovery/stabilization
to a temporary improvement of the blink reflex. In several cases,
the treatment response was not documented by objective
measurement (and therefore may have beenmerely subjective)
or perhaps not clinically relevant (temporary improvement of
blink reflex), making the effect debatable. There have been no
placebo-controlled studies of immunotherapy.
Multiple lines of evidence seem to support the hypothesis
that FOSMN is a neurodegenerative disorder. Perhaps most
convincing is that the autopsies of 4 FOSMN cases revealed
intraneuronal TDP-43 inclusions, which is the pathologic
hallmark of ALS and FTD.
In a journal supplement, 2 patients with FOSMNarementioned,
in which postmortem examination also revealed TDP-43 ag-
gregates in themotor and sensory trigeminal nucleus and anterior
horn cells of the cervical and thoracic cord in patient 1 and in the
sensory and motor trigeminal nucleus and cervical, thoracic,
and lumbar motor neurons, with associated astrocytosis, in pa-
tient 2.32 Unfortunately, we only had access to the abstract, but
these findings also support the neurodegenerative etiology.
Furthermore, a link to ALS has been suggested after a patient
with FOSMN was found to harbor a heterozygous mutation in
the familial ALS gene for SOD1. This specific mutation (D90A)
generally causes a recessive form of ALS, although there are
several pedigrees in which this mutation appears to cause disease
in an autosomal dominant manner. It is therefore unclear
whether thismutation should be considered pathogenic.33Other
cases of FOSMN with mutations related to ALS have also been
found. Two cases with a heterozygous TARDBPmutation, both
considered pathogenic,10,11 a heterozygous pathogenic VCP
mutation and a heterozygous pathogenic CHCHD10 muta-
tion.11 Finally, there was a patient with 2 heterozygousmutations
in the TARDBP and in SQSTM1 genes. In this case, it was
suggested that the combination of the mutations resulted in this
phenotype.24 Some of these patients had a positive family history
of ALS or other neurodegenerative diseases. Four patients with
a positive family history of FTD-ALS, ALS, FTD, and or Par-
kinson disease, but without definitive results from genetic testing,
were also reported.11 This suggests that these diseases may
cluster with pedigrees, like other neurodegenerative diseases.34,35
The fact that patients develop severe bulbar symptoms with
respiratory insufficiency (reminiscent of ALS) and may de-
velop cognitive and behavioral changes within the FTD
spectrum supports considering FOSMN as part of the FTD-
Multiple lines of evidence seem to
support the hypothesis that FOSMN
is a neurodegenerative disorder.
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MND continuum. Indeed, findings at autopsy have also
provided evidence that FOSMN may be a TDP-43
proteinopathy.
TDP-43 pathology is seen in approximately 98% of patients
with ALS, but is absent in the 2% of ALS that can be attributed
to SOD1mutations.33,36 The presence of TDP-43 pathology
and the identification of an SOD1 mutation suggest a con-
nection to ALS, and although there is some limited evidence
in support of an autoimmune mechanism, this is far from
conclusive. Our tentative conclusion is that FOSMN is most
likely to have a neurodegenerative etiology, possibly within
the ALS-FTD continuum.
To determine the underlying cause of FOSMN, more re-
search is needed through an international collaboration
considering the rare nature of the disease. The development
of diagnostic criteria followed by validation is an important
first step. A better understanding of the natural history of the
disease will aid physicians in providing their patients with the
appropriate care. Further characterization of the disease, in
particular whether FOSMN is a TDP-43 proteinopathy, may
provide inroads into therapy options based on insights from
other TDP-43–related disorders.
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TAKE-HOME POINTS
FOSMN is an extremely rare neurologic disease
starting with sensory impairment in the face
spreading along a craniocaudal distribution, fol-
lowed bymotor involvement spreading by the same
pattern.
FOSMN resembles ALS in the sense that motor
impairment results in weakness, eventual need for
gastronomy, and in most cases respiratory failure.
Disease duration, however, is longer than for
patients with ALS.
Although not conclusive, the balance of evidence
suggests that FOSMN is most likely to be a TDP-43
proteinopathy within the ALS-FTD spectrum. This is
supported by the resembling disease progression,
presence of TDP-43 pathology, and genetic muta-
tions associated with MNDs found in patients with
FOSMN.
Further (international) research is required to form
diagnostic criteria and to obtain further knowledge
on FOSMN.
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